Male Hypogonadism - Global Market Trajectory & Analytics

Global Male Hypogonadism Market to Reach $3.5 Billion by 2027

Amid the COVID-19 crisis, the global market for Male Hypogonadism estimated at US$2.8 Billion in the year 2020, is projected to reach a revised size of US$3.5 Billion by 2027, growing at a CAGR of 2.9% over the period 2020-2027. Testosterone Replacement Therapy, one of the segments analyzed in the report, is projected to record 2.7% CAGR and reach US$2 Billion by the end of the analysis period. After an early analysis of the business implications of the pandemic and its induced economic crisis, growth in the Gonadotropin & Gonadotropin Releasing Hormones Therapy segment is readjusted to a revised 3.2% CAGR for the next 7-year period.



The U.S. Market is Estimated at $830.8 Million, While China is Forecast to Grow at 2.8% CAGR

The Male Hypogonadism market in the U.S. is estimated at US$830.8 Million in the year 2020. China, the world`s second largest economy, is forecast to reach a projected market size of US$618.1 Million by the year 2027 trailing a CAGR of 2.8% over the analysis period 2020 to 2027. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 2.7% and 2.4% respectively over the 2020-2027 period. Within Europe, Germany is forecast to grow at approximately 3% CAGR.

Select Competitors (Total 47 Featured):

• AbbVie, Inc.
• Allergan PLC
• AstraZeneca PLC
• Bayer AG
• Eli Lilly and Company
• Endo International PLC
• Ferring International Center SA
• IBSA Institut Biochimique SA
• Laboratoires Genevrier
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.